Navarra is
once again playing a leading role in biomedical research in Spain. The
University Hospital of Navarra (HUN) has launched a multicentre Phase Ib/II
clinical trial to evaluate a new therapeutic strategy for small-cell lung cancer,
a particularly aggressive disease with limited treatment options when it
returns.
once again playing a leading role in biomedical research in Spain. The
University Hospital of Navarra (HUN) has launched a multicentre Phase Ib/II
clinical trial to evaluate a new therapeutic strategy for small-cell lung cancer,
a particularly aggressive disease with limited treatment options when it
returns.
The first
patient has already received treatment, and the trial is expected to involve at
least nine hospitals across Spain and a total of 60 patients over the coming
months.
patient has already received treatment, and the trial is expected to involve at
least nine hospitals across Spain and a total of 60 patients over the coming
months.
Exploring
a new approach to cancer treatment
a new approach to cancer treatment
The
clinical trial will evaluate IDP-121, an experimental drug designed to target
the MYC protein, which plays an important role in tumour growth and
progression.
clinical trial will evaluate IDP-121, an experimental drug designed to target
the MYC protein, which plays an important role in tumour growth and
progression.
The drug
will be studied in combination with conventional chemotherapy to assess its
safety and potential therapeutic activity.
will be studied in combination with conventional chemotherapy to assess its
safety and potential therapeutic activity.
This
research is particularly significant because small-cell lung cancer accounts
for approximately 15% of all lung cancer cases and has a high recurrence rate.
Developing new treatment strategies therefore remains an important priority in
oncology research.
research is particularly significant because small-cell lung cancer accounts
for approximately 15% of all lung cancer cases and has a high recurrence rate.
Developing new treatment strategies therefore remains an important priority in
oncology research.
Connecting
hospitals, science and biotechnology
hospitals, science and biotechnology
One of the
most valuable aspects of the project is the collaboration between different
organisations within Navarra’s healthcare and research ecosystem.
most valuable aspects of the project is the collaboration between different
organisations within Navarra’s healthcare and research ecosystem.
The trial
is being developed by the University Hospital of Navarra, Navarrabiomed and the
Navarra Institute for Health Research (IdISNA), with biotechnology company IDP
Pharma acting as the study sponsor.
is being developed by the University Hospital of Navarra, Navarrabiomed and the
Navarra Institute for Health Research (IdISNA), with biotechnology company IDP
Pharma acting as the study sponsor.
The
research is led by Dr Hugo Arasanz Esteban, a medical oncologist at the
University Hospital of Navarra and researcher at Navarrabiomed.
research is led by Dr Hugo Arasanz Esteban, a medical oncologist at the
University Hospital of Navarra and researcher at Navarrabiomed.
This
collaboration highlights the importance of bringing together clinical
expertise, biomedical research and biotechnology to advance scientific
knowledge and explore new approaches to complex diseases.
collaboration highlights the importance of bringing together clinical
expertise, biomedical research and biotechnology to advance scientific
knowledge and explore new approaches to complex diseases.
Navarra:
where talent drives healthcare innovation
where talent drives healthcare innovation
Beyond its
medical objectives, this clinical trial demonstrates Navarra’s ability to lead
research projects with a nationwide impact.
medical objectives, this clinical trial demonstrates Navarra’s ability to lead
research projects with a nationwide impact.
Developing
new therapies requires multidisciplinary teams, bringing together professionals
from medicine, biomedical sciences, biotechnology, pharmacy, clinical research,
data analysis and other scientific fields.
new therapies requires multidisciplinary teams, bringing together professionals
from medicine, biomedical sciences, biotechnology, pharmacy, clinical research,
data analysis and other scientific fields.
For
international professionals interested in pursuing careers in healthcare and
life sciences, initiatives like this offer a glimpse into the projects and
collaborations taking place within Navarra’s research ecosystem.
international professionals interested in pursuing careers in healthcare and
life sciences, initiatives like this offer a glimpse into the projects and
collaborations taking place within Navarra’s research ecosystem.
At Navarra
Talent, we believe these developments highlight something important: Navarra is
not only a place to build a career, but also an environment where knowledge,
collaboration and specialised talent can contribute to addressing some of
medicine’s greatest challenges.
Talent, we believe these developments highlight something important: Navarra is
not only a place to build a career, but also an environment where knowledge,
collaboration and specialised talent can contribute to addressing some of
medicine’s greatest challenges.
Because
behind every scientific breakthrough, there is talent opening up new
possibilities.
behind every scientific breakthrough, there is talent opening up new
possibilities.
